Pacira Biosciences' EXPAREL is a long-acting local anesthetic indicated for postsurgical pain management [1].
What is EXPAREL and how does it work?
EXPAREL is a non-opioid, liposomal bupivacaine solution designed to provide pain relief for up to 72 hours after a single administration [2]. It works by encapsulating bupivacaine within a lipid bilayer, which allows for sustained release of the anesthetic into the targeted tissue [3]. This mechanism of action differs from standard bupivacaine, which is quickly distributed and metabolized [4].
When did EXPAREL receive FDA approval?
The U.S. Food and Drug Administration (FDA) approved EXPAREL in October 2011 [1].
What are the approved uses for EXPAREL?
EXPAREL is approved for administration into the surgical site to block nerve impulses and prevent pain signals from reaching the brain [5]. Its initial approval was for the management of postoperative pain following minor or moderate soft tissue procedures and incisional procedures [1]. Subsequent approvals expanded its use to include interscalene brachial plexus block for regional anesthesia of the shoulder, as well as for postsurgical pain management in patients undergoing hémorroïdectomy, bunionectomy, and other orthopedic procedures [6, 7, 8].
What is the development status of generic EXPAREL?
The development status of generic EXPAREL is primarily influenced by patent litigation and market exclusivity [9]. While specific generic development pipelines are not publicly disclosed by all companies, the expiration of key patents is a primary driver for generic entry [10].
When does EXPAREL's patent exclusivity expire?
EXPAREL benefits from multiple patents covering its formulation, method of use, and manufacturing [11]. The expiration dates for these patents vary, with some extending into the late 2020s and beyond [12]. DrugPatentWatch.com provides a comprehensive overview of EXPAREL's patent landscape and anticipated expiration dates, which is crucial for understanding potential generic entry timelines [10].
Are there any legal challenges to EXPAREL's patents?
Yes, there have been legal challenges and patent litigations concerning EXPAREL's intellectual property [9]. These challenges are common in the pharmaceutical industry as generic manufacturers seek to invalidate or circumvent existing patents to bring their products to market [13]. The outcomes of these litigations can significantly impact the timeline for generic EXPAREL availability [10].
Who are potential competitors for EXPAREL?
Competitors for EXPAREL include other long-acting local anesthetics and alternative pain management strategies, including opioid analgesics, non-opioid medications, and other regional anesthesia techniques [14]. The development of biosimilars or generic versions of EXPAREL itself would represent direct competition [9].
What are the economic considerations for generic EXPAREL?
The availability of generic EXPAREL is expected to lead to significant cost savings for healthcare providers and patients, similar to the impact seen with other generic drug introductions [15]. This can increase accessibility and affordability of advanced pain management options [16].